EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-10.99%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.94B
AUM Growth
+$2.94B
(-23%)
Cap. Flow
-$70.7M
Cap. Flow
% of AUM
-2.41%
Top 10 Holdings %
Top 10 Hldgs %
73.2%
Holding
58
New
6
Increased
6
Reduced
4
Closed
8
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$250M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$207M |
| 3 |
Tango Therapeutics
TNGX
|
$52.6M |
| 4 |
Neumora Therapeutics
NMRA
|
$29.2M |
| 5 |
Arvinas
ARVN
|
$28.5M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$419M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$114M |
| 3 |
Spyre Therapeutics
SYRE
|
$58.8M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$54.2M |
| 5 |
Revolution Medicines
RVMD
|
$44.9M |
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $559M | 18.85% | 11,584,280 | – | – |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $415M | 13.99% | 10,899,859 +5,448,212 | +100% | +$207M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $250M | 8.45% | +5,748,399 | New | +$250M |
|
4
Galapagos
GLPG
$2.07B
| $199M | 6.71% | 5,756,268 | – | – |
|
|
5
Revolution Medicines
RVMD
$7.1B
| $154M | 5.21% | 5,577,863 -1,620,837 | -23% | -$44.9M |
|
6
AnaptysBio
ANAB
$569M
| $135M | 4.56% | 7,521,024 | – | – |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $125M | 4.21% | 5,991,479 | – | – |
|
|
8
Arvinas
ARVN
$568M
| $107M | 3.62% | 5,467,063 +1,449,275 | +36% | +$28.5M |
|
9
Xencor
XNCR
$580M
| $106M | 3.59% | 5,282,516 | – | – |
|
|
10
Tango Therapeutics
TNGX
$747M
| $98.2M | 3.31% | 8,721,636 +4,674,522 | +116% | +$52.6M |
|
11
Zymeworks
ZYME
$1.12B
| $85.2M | 2.87% | 13,437,473 | – | – |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $80M | 2.7% | 3,460,208 | – | – |
|
13
Kura Oncology
KURA
$686M
| $53M | 1.79% | 5,806,871 | – | – |
|
14
Jazz Pharmaceuticals
JAZZ
$7.75B
| $47.7M | 1.61% | 368,411 | – | – |
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $45.5M | 1.54% | 1,530,263 +200,000 | +15% | +$5.95M |
|
|
CNTA
16
Centessa Pharmaceuticals
CNTA
$2.25B
| $36.4M | 1.23% | 5,618,779 | – | – |
|
17
Relay Therapeutics
RLAY
$619M
| $35M | 1.18% | 4,163,824 | – | – |
|
|
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $33.9M | 1.14% | 1,480,190 -2,366,774 | -62% | -$54.2M |
|
19
Voyager Therapeutics
VYGR
$186M
| $29.8M | 1.01% | 3,851,507 | – | – |
|
|
20
Neumora Therapeutics
NMRA
$280M
| $29.2M | 0.99% | +2,071,450 | New | +$29.2M |
|
21
Alector
ALEC
$238M
| $26.3M | 0.89% | 4,056,548 | – | – |
|
22
Nuvation Bio
NUVB
$1.02B
| $25.7M | 0.87% | 19,209,643 +5,313,100 | +38% | +$7.12M |
|
23
Mersana Therapeutics
MRSN
$36.5M
| $24.6M | 0.83% | +19,364,688 | New | +$24.6M |
|
24
Ovid Therapeutics
OVID
$91M
| $23.5M | 0.79% | 6,117,400 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $21.2M | 0.71% | 8,538,446 | – | – |
|